CP-532,903

CP-532,903
Names
	IUPAC name (2S,3S,4R,5R)-3-amino-5-[6-(2,5-dichlorobenzylamino)purin-9-yl]-4-hydroxytetrahydrofuran-2-carboxylic acid methylamide
	Other names CP-532,903
Identifiers
CAS Number	457612-59-8 ;
3D model (JSmol)	Interactive image; Interactive image;
ChemSpider	8654410 ;
PubChem <abbr title="<nowiki>Compound ID</nowiki>">CID	10479002;
CompTox Dashboard (<abbr title="<nowiki>U.S. Environmental Protection Agency</nowiki>">EPA)	DTXSID40440587 ;
	InChI InChI=1S/C18H19Cl2N7O3/c1-22-17(29)14-11(21)13(28)18(30-14)27-7-26-12-15(24-6-25-16(12)27)23-5-8-4-9(19)2-3-10(8)20/h2-4,6-7,11,13-14,18,28H,5,21H2,1H3,(H,22,29)(H,23,24,25)/t11-,13+,14-,18+/m0/s1 Key: WFRYPIJMCFQCGT-MHMFGPJMSA-N ; InChI=1/C18H19Cl2N7O3/c1-22-17(29)14-11(21)13(28)18(30-14)27-7-26-12-15(24-6-25-16(12)27)23-5-8-4-9(19)2-3-10(8)20/h2-4,6-7,11,13-14,18,28H,5,21H2,1H3,(H,22,29)(H,23,24,25)/t11-,13+,14-,18+/m0/s1 Key: WFRYPIJMCFQCGT-MHMFGPJMBE;
	SMILES Clc3ccc(Cl)cc3CNc(c1nc4)ncnc1n4C(C(O)C2N)OC2C(=O)NC; Clc1cc(c(Cl)cc1)CNc4ncnc2c4ncn2[C@@H]3O[C@H](C(=O)NC)[C@@H](N)[C@H]3O;
Properties
Chemical formula	C18H19Cl2N7O3
Molar mass	452.294
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
	verify (what is ?)
	Infobox references

CP-532,903 là một chất chủ vận thụ thể adenosine A₃ chọn lọc. Nó có tác dụng chống viêm và đã được chứng minh là làm giảm sự sản sinh superoxit trong các mô bị tổn thương,^[1] và bảo vệ chống lại tổn thương mô sau thiếu máu cơ tim,^[2] qua trung gian thông qua tương tác với các kênh kali nhạy cảm ATP.^[3]

Tham khảo[sửa | sửa mã nguồn]

^ van der Hoeven D, Wan TC, Auchampach JA. Activation of the A(3) adenosine receptor suppresses superoxide production and chemotaxis of mouse bone marrow neutrophils. Molecular Pharmacology. 2008 Sep;74(3):685-96.
^ Tracey WR, Magee WP, Oleynek JJ, Hill RJ, Smith AH, Flynn DM, Knight DR. Novel N6-substituted adenosine 5'-N-methyluronamides with high selectivity for human adenosine A3 receptors reduce ischemic myocardial injury. American Journal of Physiology. Heart and Circulatory Physiology. 2003 Dec;285(6):H2780-7. PMID 12919933
^ Wan TC, Ge ZD, Tampo A, Mio Y, Bienengraeber MW, Tracey WR, Gross GJ, Kwok WM, Auchampach JA. The A3 adenosine receptor agonist CP-532,903 [N6-(2,5-dichlorobenzyl)-3'-aminoadenosine-5'-N-methylcarboxamide] protects against myocardial ischemia/reperfusion injury via the sarcolemmal ATP-sensitive potassium channel. Journal of Pharmacology and Experimental Therapeutics. 2008 Jan;324(1):234-43. doi:10.1124/jpet.107.127480 PMID 17906066

[1] van der Hoeven D, Wan TC, Auchampach JA. Activation of the A(3) adenosine receptor suppresses superoxide production and chemotaxis of mouse bone marrow neutrophils. Molecular Pharmacology. 2008 Sep;74(3):685-96.

[2] Tracey WR, Magee WP, Oleynek JJ, Hill RJ, Smith AH, Flynn DM, Knight DR. Novel N6-substituted adenosine 5'-N-methyluronamides with high selectivity for human adenosine A3 receptors reduce ischemic myocardial injury. American Journal of Physiology. Heart and Circulatory Physiology. 2003 Dec;285(6):H2780-7. PMID 12919933

[3] Wan TC, Ge ZD, Tampo A, Mio Y, Bienengraeber MW, Tracey WR, Gross GJ, Kwok WM, Auchampach JA. The A3 adenosine receptor agonist CP-532,903 [N6-(2,5-dichlorobenzyl)-3'-aminoadenosine-5'-N-methylcarboxamide] protects against myocardial ischemia/reperfusion injury via the sarcolemmal ATP-sensitive potassium channel. Journal of Pharmacology and Experimental Therapeutics. 2008 Jan;324(1):234-43. doi:10.1124/jpet.107.127480 PMID 17906066

[1]

[2]

[3]